21.65 0.00 (0.00%)
After hours: 4:21PM EDT
|Bid||17.15 x 2900|
|Ask||30.00 x 1000|
|Day's Range||21.35 - 21.90|
|52 Week Range||11.93 - 25.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
GI Partners is buying two medical-storage companies to take advantage of the growing reproductive sciences field. GI is also buying California Cryobank, a donor sperm and egg bank, from health-care investors Longitude Capital and NovaQuest Capital, for an undisclosed amount. California Cryobank’s donor sperm and egg banks have worked with more than 75,000 families since 1977.
The Waltham, Massachusetts-based company said it had a loss of $1.59 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
I am going to run you through how I calculated the intrinsic value of AMAG Pharmaceuticals Inc (NASDAQ:AMAG) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
AMAG Pharma (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Waltham, Massachusetts-based company said it had profit of 10 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Moody's Investors Service says a supplemental regulatory approval of AMAG Pharmaceuticals, Inc.'s ("AMAG") next generation Makena drug-device combination product is credit positive. The approval ...
What Led to Stellar Rise of AMAG Pharmaceuticals in February? AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company with a focus on clinical research and the development of therapeutics. AMAG also provides services for preserving umbilical cord stem cells and cord tissue units through cord blood registry.
Amag increased its value by nearly a third Thursday after U.S. regulators approved a second drug from the biotech this month.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares are skyrocketing Thursday as the company received regulatory approval for one of its treatments. The company announced that the U.S. Food and Drug Administration gave the green light for its Makena subcutaneous auto injector drug-device combination product, which is a treatment that is designed to reduce the risk of preterm birth in women who are pregnant with one baby, as well as those who spontaneously delivered one preterm baby in the past. AMAG Pharmaceuticals developed the medication along with Antares Pharma Inc (NASDAQ:ATRS) as the two companies agreed back in a 2014 deal that AMAG will make and supply the drug product to Antares.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Cisco Systems, Inc. (NASDAQ: CSCO ) stock was trading ...
Below is a list of notable corporate events for the week beginning Feb. 12. Note, this list is not comprehensive and all dates are subject to change. Monday Economics Pres. Trump Monday unveiled his plans ...
Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of AMAG Pharmaceuticals Inc (NASDAQ:AMAG) as an investment opportunity. If youRead More...
In September 2017, AMAG Pharmaceuticals Inc (NASDAQ:AMAG) announced its latest earnings update, which suggested that the company entered the red zone with earnings dropping into the negative territory due toRead More...